Lung cancer in the era of targeted therapy: A cytologist's perspective

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 12, 2013, Pages 1816-1821

  Zakowski, Maureen F ^a  

^a Memorial Sloan Kettering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892683781     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0029-RA     Document Type: Review

References (39)

1. Kaiser J. Cancer research: looking for a target on every tumor. Science. 2009;326(5950):218-220.
2. Hayden EC. Personalized cancer therapy gets closer. Nature. 2009;458(7235):131-132.
3. Varmus H. The new era in cancer research. Science. 2006;312(5777):1162- 1165.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
5. American Cancer Society. Cancer Facts & Figures, 2012. Atlanta, GA: American Cancer Society; 2012.
6. Aberle DR, Adams AM, Berg CD, et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.
7. Sakr L, Roll P, Payan MJ, et al. Cytology-based treatment decision in primary lung cancer: is it accurate enough? [published online ahead of print October 5, 2011]. Lung Cancer. 2012;75(3):293-299.
8. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101(36):13306-13311.
9. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012;18(4):1167-1176.
10. Pao W, Iafrate AJ, Su Z. Genetically informed lung cancer medicine. J Pathol. 2011;223(2):230-240.
11. Murakami Y, Mitsudomi T, Yatabe Y. A screening method for the ALK fusion gene in NSCLC. Front Oncol. 2012;2:24. doi: 10.3389/fonc.2012.00024.
12. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73. doi:10.1371/journal. pmed.0020073.
13. XALKORI (crizotinib) capsules, oral [package insert]. New York, NY: Pfizer Laboratories; 2011.
14. Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC. The evolving role of histology in the management of advanced non-small cell lung cancer. J Clin Oncol. 2010;28(36):5311-5320.
15. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139.
16. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500.
17. Zakowski MF, Hussain S, Pao W, et al. Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Arch Pathol Lab Med. 2009;133(3):470-477.
18. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008;26(9):1472-1478.
19. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32(6):810-827.
20. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866-2874.
21. Sholl LM, Xiao Y, Joshi V, et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol. 2010;133(6):922-934.
22. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011;6(3):451-458.
23. Nizzoli R, Tiseo M, Gelsomino F, et al. Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. J Thorac Oncol. 2011;6(3):489-493.
24. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer. 2011;117(15):3416-3423.
25. Sigel CS, Moreira AL, Travis WD, et al. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol. 2011;6(11):1849-1856.
26. Pelosi G, Fabbri A, Bianchi F, et al. DNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol. 2012;7(2):281-290.
27. Azzoli CG, Baker S Jr, Temin S, et al; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol. 2009;27(36):6251-6266.
28. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: non-small cell lung cancer, version 2.2012 NCCN Guidelines Web site. http://www.nccn.org/professionals/physician-gls/PDF/nscl.pdf. Accessed November 28, 2011.
29. Nakajima T, Yasufuku K, Suzuki M, et al. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest. 2007;132(2):597-602.
30. Schuurbiers OC, Looijen-Salamon MG, Ligtenberg MJ, van der Heijden HF. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates. J Thorac Oncol. 2010;5(10):1664-1667.
31. Smouse JH, Cibas ES, Janne PA, Joshi VA, Zou KH, Lindeman NI. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer. 2009;117(1):67-72.
32. Clark DP. Seize the opportunity: underutilization of fine-needle aspiration biopsy to inform targeted cancer therapy decisions. Cancer. 2009;117(5):289-297.
33. Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011;17(5):1169-1180.
34. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17(6):1616-1622.
35. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010;12(2):169-176.
36. Ang D, Brevet M, Ladanyi M, Zakowski MF. Assessment of EGFR mutation status in needle biopsies and cytology specimens of lung adenocarcinoma by immunohistochemistry using antibodies to two major forms of mutant EGFR. Lab Invest. 2010;90(suppl 1):87A.
37. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small cell lung cancers into routine clinical practice. Ann Oncol. 2011;22(12):2616-2624.
38. Brandt SM, Tafe LJ, Arcila ME, et al. Performance of cytologic specimens in EGFR and KRAS molecular testing with a focus on minimal cellularity requirements. Mod Pathol. 2011;24(suppl 1):405A-406A.
39. Lauwers GY, Black-Schaffer S, Salto-Tellez M. Molecular pathology in contemporary diagnostic pathology laboratory: an opinion for the active role of surgical pathologists. Am J Surg Pathol. 2010;34(1):115-117.